首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   386891篇
  免费   29480篇
  国内免费   11020篇
耳鼻咽喉   2571篇
儿科学   9966篇
妇产科学   4514篇
基础医学   41700篇
口腔科学   6871篇
临床医学   34515篇
内科学   76031篇
皮肤病学   4812篇
神经病学   36935篇
特种医学   12424篇
外国民族医学   4篇
外科学   30037篇
综合类   52462篇
现状与发展   52篇
一般理论   17篇
预防医学   31729篇
眼科学   4584篇
药学   39513篇
  224篇
中国医学   21945篇
肿瘤学   16485篇
  2024年   844篇
  2023年   6315篇
  2022年   11789篇
  2021年   18363篇
  2020年   16237篇
  2019年   13801篇
  2018年   13787篇
  2017年   14421篇
  2016年   14779篇
  2015年   14057篇
  2014年   22004篇
  2013年   27188篇
  2012年   21026篇
  2011年   23839篇
  2010年   17143篇
  2009年   16843篇
  2008年   18276篇
  2007年   18906篇
  2006年   17415篇
  2005年   15245篇
  2004年   13013篇
  2003年   11411篇
  2002年   9293篇
  2001年   8261篇
  2000年   6901篇
  1999年   5884篇
  1998年   5085篇
  1997年   4875篇
  1996年   4425篇
  1995年   3907篇
  1994年   3701篇
  1993年   3127篇
  1992年   2934篇
  1991年   2693篇
  1990年   2238篇
  1989年   1857篇
  1988年   1751篇
  1987年   1598篇
  1986年   1441篇
  1985年   1911篇
  1984年   1552篇
  1983年   1091篇
  1982年   1181篇
  1981年   979篇
  1980年   877篇
  1979年   717篇
  1978年   479篇
  1977年   422篇
  1976年   372篇
  1975年   235篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
72.
AimsThe effect of Origanum majorana tea consumption on motor and non-motor symptoms was investigated in patients with idiopathic Parkinson's disease, measured by validated tools.MethodsSixty patients with idiopathic Parkinson's disease and under conventional medication were enrolled voluntarily in the study. All participants were randomized on double-blind to placebo or Origanum majorana. Clinical assessment with validated tools (UPDRSIII, NMSS, and BDI) was done before Origanum majorana or placebo consumption (Day 0) and at the end of the experiment (Day 30).ResultsThe treatment groups were similar at baseline on demographic and clinical variables. During the course of study, nine participants withdrew for reasons of noncompliance and inability to follow-up. Fifty-one participants completed the study. Upon completion of 30 days of treatment, Origanum majorana tea consumption did not decrease the UPDRSIII score ([UPDRSIII] D0 = 18.76 ± 8.58, D30 = 16.52 ± 7.96, p = 0.069) at the p value was 0.07. However, a statistically significant improvement was noted in NMSS and BDI scores (p < 0.0001 and p < 0.0001, respectively). Assessment of the UPDRSIII, NMSS and BDI scores of the patients did not reflect any improvement with placebo. No side effect was detected during the study.ConclusionThese findings show improvement of depressive and non-motor signs in patients with Parkinson's disease in the group that consumed Origanum majorana tea in combination with conventional therapy. Improvement of motor signs may need an extended treatment period. However, more research with a large number of participants and lasting longer than 1 month is needed to argue these findings.  相似文献   
73.
74.
75.
Context: Treatment of primary spinal syringomyelia is still controversial. Among others, shunting syrinx fluid to the subarachnoid, peritoneal or pleural space has been utilized with varying success. Shunt obstruction, migration, and infection represent the most common complications of these procedures.

Findings: The authors present the case of an 81-year-old woman who developed an unusual neurological deterioration resembling a subacute posttraumatic ascending myelopathy (SPAM) after the insertion of a syringosubarachnoid shunt for the treatment of slow-growing D10 syringomyelia.

Conclusion/Clinical Relevance: To date, no cases of SPAM secondary to the insertion of a syringosubarachnoid shunt for the treatment of syringomyelia have been reported. The potential pathogenesis related to this phenomenon is discussed.  相似文献   
76.
《Clinical neurophysiology》2020,131(7):1444-1452
ObjectiveTo investigate cognitive functions in non-demented patients with early-onset Parkinson's disease (PD), and to compare PARK2 gene mutation carriers and non-carriers by means of event-related brain potentials (ERPs).MethodsThe participants comprised patients with early-onset PD (EOPD) and healthy controls (HC). Patients with EOPD were divided into two groups as carriers of known pathogenic variants of PARK2 gene (EOPD-PC) and non-carriers of genes involved in familial PD (EOPD-NC). ERP data were collected during auditory oddball and visual continuous performance test (CPT).ResultsBoth EOPD groups (EOPD-PC and EOPD-NC) displayed reduced and delayed P3 in response to oddball target and CPT NoGo. CPT Go P3 was reduced in EOPD-NC but not in EOPD-PC. Oddball target N1 was reduced and P2 was enhanced in both EOPD-PC and EOPD-NC. In both cognitive tasks, RTs were prolonged and accuracy was lower in EOPD-PC and EOPD-NC.ConclusionsWe found several EOPD-related neurophysiologic changes, implying impairments in cognitive functions. Pairwise comparisons between EOPD-PC and EOPD-NC revealed no significant ERP marker.SignificanceIn this study, the confounding effect of normative aging was somewhat excluded compared with many previous studies. In contrast with the many oddball studies in non-demented PD, we clearly observed reduced and prolonged P3 in early-onset PD. Our NoGo P3 findings also contribute to the limited ERP research concerning response inhibition.  相似文献   
77.
78.
This paper describes country-wide special measures undertaken for interventional radiology staff during the current coronavirus disease 2019 (COVID-19) pandemic. Although each interventional radiology service around the world faces unique challenges, the principles outlined in this article will be useful when designing or strengthening individual practices and integrating them within wider hospital and national measures. Moving beyond the current outbreak, these measures will be useful for any future infectious diseases which are likely to arise.  相似文献   
79.
80.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号